NeoControl featured in Alternative Medicine magazine

In the April 2005 issue of the US publication Alternative Medicine, a feature article titled "May the Force Be With You" (Issue 76, pg. 74) outlined the recently escalated movement of practicing medicine utilizing pulsed electromagnetics. NeoControl was the primary entry listed under the "Devices to Know About" section. 

Indeed, ExMI technology has entered the medical mainstream.

For more information on this article and the publication, visit Alternative Medicine Online.

Currently used to treat urinary incontinence - a condition that impacts an estimated 16 million women in the U.S. alone - ExMI may have applications for a variety of other conditions, including depression, epilepsy, Alzheimer's disease and a host of other neurological disorders, providing a non-invasive alternative to traditional therapies that are often ineffective, highly invasive or beset with potentially negative side effects. "Magnetism has long been believed to have therapeutic benefits, but ExMI is the first technology to apply such powerful magnetic fields in such a precise fashion with clearly evident results," said Tony Morris, CEO of Neotonus Inc. and co-inventor of the ExMI technology. "We are excited by the potential for improving the lives of millions of people who suffer from debilitating conditions, and are diligently pursuing the appropriate clinical trials in close partnership with leading medical centers in the U.S. and abroad," added Morris.

ExMI was developed by Neotonus in 1997, and was cleared by the U.S. Food and Drug Administration in June 1998 for the treatment of stress, urge and mixed urinary incontinence in women. The first product to utilize ExMI technology, the NeoControl® Pelvic Floor Therapy System, is currently in use in more than over 150 urology and obstetrics/gynecology practices throughout the United States and 10 other countries. To date, more than 18,500 NeoControl treatments have been administered to women with impressive success rates. Data from studies at the Cleveland Clinic and sites in Chicago, Philadelphia and Orlando indicate that 50 percent of women who completed six weeks of NeoControl therapy reported being "completely dry" and an additional 30 percent reported "significant improvement" in their conditions. NeoControl employs powerful pulsing magnetic fields to stimulate nerve activity in the pelvic floor, which in turn exercises the muscles that control bladder function, improving strength and endurance and increasing circulation. While fully clothed, patients undergo a painless, non-invasive 20-minute treatment twice a week for eight weeks. Sitting in a comfortable chair, the patient will feel her muscles tighten and relax as they are exercised according to a physician's prescription.

Neotonus recently launched the first study using pulsed magnetic therapy as a non-invasive treatment for urinary incontinence among men who have undergone radical prostatectomy surgery for prostate cancer. The study offers hope to the 330,000 men who are diagnosed with prostate cancer each year, many of whom will require prostate surgery, the leading cause of incontinence in men.